AlgiPharma Phase I clinical trial shows excellent safety and tolerability data for respiratory diseases
OligoG CF-5/20 was well tolerated when administered by inhalation to 28 healthy subjects. All adverse events monitored were mild and transient. No serious adverse events, no deaths, no discontinuations.
Read more ClinicalTrials.gov
For more information contact:
Yngvar P. Berg, CEO; email@example.com
Astrid Hilde Myrset, Clinical Director; firstname.lastname@example.org